Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-CRC02
2020-004782-39Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan in colorectal cancer (CRC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Confirmed objective response rate by blinded independent central review. Started Feb 2021; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-004782-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004782-39.